Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.74 |
| ▸ | EDNRB | P24530 | 15/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | DHPS | P49366 | 1/20 | 0.74 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.74 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7211094 | 0.91 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7206023 | 0.91 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7206755 | 0.91 | EDNRA (0.78) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7206763 | 0.91 | EDNRA (0.78) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7211027 | 0.90 | EDNRA (0.83) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7206822 | 0.90 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7213128 | 0.90 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7206180 | 0.89 | EDNRA (0.73) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7206064 | 0.89 | EDNRA (0.72) | EDNRAEDNRBABCC3ABCC4NR1I2 | |
| SCHEMBL7211014 | 0.89 | EDNRA (0.74) | EDNRAEDNRBABCC3ABCC4NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6337334-B1 | SUBSTITUTED BIPYRIMIDINES WITH ETHERS AND SULFONAMIDE GROUPS COMPOUNDS EXHIBIT STRONG BINDING INHIBITORY ACTIVITY AGAINST ENDOTHELIN HAVING POTENT VASOCONSTRICTIVE EFFECT AND CELL PROLIFERATION EFFECT. | KOWA CO., LTD. (JP) | 2002-01-08 | — | — | US | claimed |
| US-6008224-A | POTENT ENDOTHELIN ANTAGONISM TREATING VASOCONSTRICTIVE EFFECT AND CELL PROLIFERATION EFFECT | KOWA CO., LTD. (JP) | 1999-12-28 | — | — | US | claimed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-0801062-B1 | PYRIMIDINE DERIVATIVES | KOWA CO (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6337334-B1 | SUBSTITUTED BIPYRIMIDINES WITH ETHERS AND SULFONAMIDE GROUPS COMPOUNDS EXHIBIT STRONG BINDING INHIBITORY ACTIVITY AGAINST ENDOTHELIN HAVING POTENT VASOCONSTRICTIVE EFFECT AND CELL PROLIFERATION EFFECT. | KOWA CO., LTD. (JP) | 2002-01-08 | — | — | US | disclosed |
| US-6008224-A | POTENT ENDOTHELIN ANTAGONISM TREATING VASOCONSTRICTIVE EFFECT AND CELL PROLIFERATION EFFECT | KOWA CO., LTD. (JP) | 1999-12-28 | — | — | US | disclosed |
| EP-0801062-A1 | PYRIMIDINE DERIVATIVES | KOWA CO. LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | EDNRA 2/4885EDNRB 1/4885ABCC3 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.